155 related articles for article (PubMed ID: 33892760)
21. Androgen-deprivation therapy in the management of neuroendocrine prostate cancer.
Martínez-Cornelio A; González-Pérez J; Tabares-García Fde J; Ramos-Salgado F; Alvarado-Cabrero I; Hernández-Toriz N
Cir Cir; 2009; 77(4):293-9; 273-8. PubMed ID: 19919791
[TBL] [Abstract][Full Text] [Related]
22. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
Park JW; Lee JK; Witte ON; Huang J
Mod Pathol; 2017 Sep; 30(9):1262-1272. PubMed ID: 28621319
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
24. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.
Azad AA; Jones EC; Chi KN
Clin Genitourin Cancer; 2014 Aug; 12(4):e151-3. PubMed ID: 24787970
[No Abstract] [Full Text] [Related]
25. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
26. Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates.
Cantley RL; Wang X; Reichert ZR; Chinnaiyan AM; Mannan R; Cao X; Spratt DE; Vaishampayan UN; Alumkal JJ; Morgan TM; Palapattu G; Davenport MS; Pantanowitz L; Mehra R
Cancer Cytopathol; 2023 Feb; 131(2):117-135. PubMed ID: 36264673
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
28. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
29. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
30. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.
Xin Z; Zhang Y; Jiang Z; Zhao L; Fan L; Wang Y; Xie S; Shangguan X; Zhu Y; Pan J; Liu Q; Huang Y; Dong B; Xue W
Hum Pathol; 2018 Sep; 79():151-159. PubMed ID: 29885405
[TBL] [Abstract][Full Text] [Related]
31. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer with neuroendocrine differentiation--case report.
Glück G; Mihai M; Stoica R; Andrei R; Sinescu I
J Med Life; 2012 Feb; 5(1):101-4. PubMed ID: 22574096
[TBL] [Abstract][Full Text] [Related]
33. Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy.
Patel R; Faiena I; Geltzeiler J
Can J Urol; 2015 Apr; 22(2):7752-4. PubMed ID: 25891342
[TBL] [Abstract][Full Text] [Related]
34. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
[TBL] [Abstract][Full Text] [Related]
35. [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype].
Bonkhoff H; Fixemer T
Pathologe; 2005 Nov; 26(6):453-60. PubMed ID: 16195860
[TBL] [Abstract][Full Text] [Related]
36. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
[TBL] [Abstract][Full Text] [Related]
37. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
38. Liver metastases in prostate carcinoma: clinical characteristics and outcome.
Pouessel D; Gallet B; Bibeau F; Avancès C; Iborra F; Sénesse P; Culine S
BJU Int; 2007 Apr; 99(4):807-11. PubMed ID: 17155968
[TBL] [Abstract][Full Text] [Related]
39. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
[TBL] [Abstract][Full Text] [Related]
40. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]